# Planetary Technologies

> Planetary Technologies is a VC fund backing Biotechnology and Life Science. See 20 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seattle, United States
- Total investments: 20
- Last investment: Jul 2026
- Lead investor: 35%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/bioeconomy-capital
- X (Twitter): https://twitter.com/BioeconomyCap
- Website: http://www.bioeconomycapital.com

Planetary Technologies is a VC fund in Seattle focused on Biotechnology and Life Science. Bioeconomy Capital invests in early-stage companies with the goal of accelerating the biotechnology revolution. Based on its startup operational expertise, product development experience, and globally recognized strategic analysis, it has developed a blueprint for building and deploying technological capabilities that will become a criticalinfrastructure of the 21st-century economy.The company's proprietary blueprint is the distillation of the fund managers'​ five decades of combined experience in synthetic biology and other engineering fields and cannot be readily duplicated. Prior investments include Zymergen, Riffyn, Synthace, RoosterBio, Arzeda, Bellwether Bio, EdenWorks, and Lumen Biosciences.

## Contacts

5 contacts available for Planetary Technologies. Shizune tracks 2 team members at Planetary Technologies. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bioeconomy-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 40% |
| Life Science | 4 | 20% |
| Chemical | 2 | 10% |
| Genetics | 2 | 10% |
| Software | 2 | 10% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 8 | 40% |
| Series B | 4 | 20% |
| Seed | 3 | 15% |
| Funding Round | 2 | 10% |
| Series C | 1 | 5% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 45% |
| United Kingdom | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Rik Wehbring | Managing Director | 2 | https://shizune.co/investors/profile/rik-wehbring |
| Rob Carlson | Managing Director & Co-Founder | 3 | https://shizune.co/investors/profile/rob-carlson |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ZymeCO | ZymeCO is a bio-manufacturing company that develops enzyme-based biological products designed for sustainable agriculture and turf management. The company utilizes a bio-process that transforms organic matter to build soil health, accelerate residue decomposition, and boost plant growth. | $4M | Series A | Jul 01, 2026 |  |
| Parse Biosciences | Parse Bio is a biotechnology startup company developing single-cell sequencing kit solutions for researchers.By using combinatorial cDNA barcoding within cells themselves, Parse Biosciences’s technology allows researchers to eliminate the need for complex and expensive microfluidic instruments. Additionally, the company’s technology enablessamples to be fixed, frozen, and stored, allowing researchers to separate out the sample extraction from downstream library preparation steps. This capability empowers researchers to run fixed samples collected on different dates together in a single experiment, providing greater control over sample handling and reducing handling errors. Split Biosciences rebranded as Parse Biosciences in 2020.The Seattle, Washington-based biotech company was established in 2018 by Alex Rosenberg, Charlie Roco, and Georg Friedrich Seelig. | $50M | Series C | Dec 14, 2023 |  |
| Tandem PV | Mechanically-stacked perovskite+silicon tandem solar panels provide a unique opportunity for solar to reach new heights | $6M | Series A | Apr 20, 2022 |  |
| Arzeda | Arzeda develops innovative products powered by its Intelligent Protein Design Technology, using generative AI-driven design to create, validate, and manufacture new proteins and enzymes that enhance our lives and protect our planet. Arzeda commercializes with Fortune 500 go-to-market partners across multiple industries, enabling higher-performing,more cost-effective solutions that are healthier and sustainable. | $36.7M | Series B | Mar 29, 2022 |  |
| Parse Biosciences | Parse Bio is a biotechnology startup company developing single-cell sequencing kit solutions for researchers.By using combinatorial cDNA barcoding within cells themselves, Parse Biosciences’s technology allows researchers to eliminate the need for complex and expensive microfluidic instruments. Additionally, the company’s technology enablessamples to be fixed, frozen, and stored, allowing researchers to separate out the sample extraction from downstream library preparation steps. This capability empowers researchers to run fixed samples collected on different dates together in a single experiment, providing greater control over sample handling and reducing handling errors. Split Biosciences rebranded as Parse Biosciences in 2020.The Seattle, Washington-based biotech company was established in 2018 by Alex Rosenberg, Charlie Roco, and Georg Friedrich Seelig. | $41.5M | Series B | Feb 15, 2022 |  |
| MicroByre | MicroByre is a platform for bacterial domestication. Their automated characterization pipeline gathers the oft-overlooked data that highlights unleveraged bacteria that meet functional industrial criteria. That is, they rapidly find the bacteria with naturally unfussy eating habits and evolution-honed metabolisms that have the potential to convertunrefined biomasses into commodity chemicals at vastly improved efficiencies compared to extant fermentation processes. They select from these functionally de-risked bacteria those which can be directly genetically modified to improve their cost profiles — even if they have never been engineered before. The data from our unique characterization pipeline informs the minimally precise genetic modifications necessary to increase pliability and yield, eliminate nutritional additives, maximize feedstock utilization, and improve contamination tolerance & phage resistance. MicroByre gives biomass conversion a truly competitive edge against petrochemical synthesis.MicroByre’s platform bridges the gap between the promising and the profitable in synthetic biology and bioengineering. A unique combination of resources and skills makes MicroByre a valuable potential partner for companies of all sizes and industries. They collaborate to define project scope to match a mutually agreeable business model, which could be a fee for service, license agreement, or joint development agreement. | $14.7M | Series A | Jan 15, 2022 |  |
| Parse Biosciences | Parse Bio is a biotechnology startup company developing single-cell sequencing kit solutions for researchers.By using combinatorial cDNA barcoding within cells themselves, Parse Biosciences’s technology allows researchers to eliminate the need for complex and expensive microfluidic instruments. Additionally, the company’s technology enablessamples to be fixed, frozen, and stored, allowing researchers to separate out the sample extraction from downstream library preparation steps. This capability empowers researchers to run fixed samples collected on different dates together in a single experiment, providing greater control over sample handling and reducing handling errors. Split Biosciences rebranded as Parse Biosciences in 2020.The Seattle, Washington-based biotech company was established in 2018 by Alex Rosenberg, Charlie Roco, and Georg Friedrich Seelig. | $7M | Series A | Jan 26, 2021 |  |
| Lumen Bioscience | Lumen Bio is a clinical-stage biotechnology company developing topically and mucosally delivered biologic drugs to treat and prevent highly prevalent diseases. | $16M | Series B | Sep 01, 2020 |  |
| iMicrobes | Industrial Microbes designs and builds microbes that produce better chemicals with lower costs and lower carbon emissions. We use greenhouse gases as the raw materials, including biogas, natural gas, and carbon dioxide. We scale our process with global chemical producers. |  | Seed | Jun 11, 2020 |  |
| RoosterBio | RoosterBio is a biotechnology company, offers synthetic biology and regenerative medicine. The team at RoosterBio leads the field of new-thinkers in stem cell research and commercialization. The company is committed to simplifying, de-risking, and de-bottlenecking your lab, liberating you to do more high-impact research.It was founded in 2012 andheadquartered in Frederick, Maryland. | $6.5M | Series B | Sep 11, 2019 |  |

10 of 20 investments shown.

## Co-investors
- [Oreilly AlphaTech Ventures](https://shizune.co/investors/profile/oreilly-alphatech-ventures) — VC Fund, 4 deals together
- [N47](https://shizune.co/investors/profile/next47) — VC Fund, 3 deals together
- [UK Innovation & Science Seed Fund](https://shizune.co/investors/profile/rainbow-seed-fund) — VC Fund, 3 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 2 deals together
- [Marshall Wace](https://shizune.co/investors/profile/marshall-wace) — VC Fund, 2 deals together
- [OS Fund](https://shizune.co/investors/profile/os-fund) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Life Science Investors](https://shizune.co/investors/life-science-investors)
- [Life Science VC Funds](https://shizune.co/investors/life-science-vc-funds)
- [Life Science Investors in United States](https://shizune.co/investors/life-science-investors-united-states)
- [Life Science Investors in United Kingdom](https://shizune.co/investors/life-science-investors-united-kingdom)
- [Life Science VC Funds in United Kingdom](https://shizune.co/investors/life-science-vc-funds-united-kingdom)

## FAQ

### What does Planetary Technologies invest in?

Planetary Technologies invests primarily in Biotechnology, Life Science and Chemical startups, most often at Series A and Series B stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Planetary Technologies?

Public channels for Planetary Technologies include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Planetary Technologies?

The team at Planetary Technologies includes Rik Wehbring (Managing Director) and Rob Carlson (Managing Director & Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co